The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) decreased by $0.0 on Friday to finish at $0.81, down -0.61 percent. The last five days have seen an average of 700,320 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$0.6500. The average number of shares traded over the last 20 days was 654,200, while the average volume over the last 50 days totaled 906,562.
ADAP stock dropped -12.90% since last month. On 08/10/23, the company’s shares reached a one-month low of $0.7900. The stock touched a high of $2.65 on 01/06/23, after rallying from a low of $0.79 in 52 weeks. The price of ADAP stock has declined by -44.52% or -$0.6500 this year, reaching a new high 4 times. Still, the stock price is down -69.43% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ADAP stock investors should be aware that Adaptimmune Therapeutics plc (ADAP) stock had its last reported insider trading activity 13 days ago on Aug 01. On Aug 01, Chief Patient Supply Officer Lunger John sold 3,096 shares at $0.91 each. This transaction resulted in the insider making $2,804. On Jul 10, Menzel Garry E sold 47,702 shares at a price of US$0.91. After the transaction, the insider now owns 75,056 shares. Chief Executive Officer Rawcliffe Adrian had earlier sold 2,333 shares on Jun 27 for $0.92 a share. The transaction was completed for $2,146.
Valuation Metrics
Beta for the stock is 2.22. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.59, the price-to-book (PB) ratio of 1.17.
Financial Health
For the three months ended June 29, Adaptimmune Therapeutics plc’s quick ratio was 3.40, while its current ratio was 3.40, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $191.11 million and revenue of $27.15 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ADAP’s return on assets (ROA) during the last 12 months has been -28.20%. There was a -203.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -89.70%.
Earnings Surprise
According to Adaptimmune Therapeutics plc’s quarterly financial report for the quarter that ended June 29, it had $127.74 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $6.67 million, while revenues rose by 11.54% to $48.28 million. It was predicted that Adaptimmune Therapeutics plc’s quarterly earnings would be -$0.12, but it ended up being -$0.13, beating the consensus by 7.70%. EBITDA was -$42.68 million for the quarter. At the end of Adaptimmune Therapeutics plc’s most recent quarter ended June 29, its liabilities totaled 216.33 million, while its total debt was $26.34 million.
Technical Picture
Here’s a quick look at Adaptimmune Therapeutics plc’s (ADAP) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 30.52%, suggesting the stock is Neutral, with a 20.65% historical volatility rate.
The stochastic %K and %D were 9.23% and 7.88% respectively, while the average true range (ATR) was 0.0536. Based on the 14-day stochastic reading of 9.52%, the RSI (14) reading is 35.17%. On the 9-day MACD Oscillator, the stock is at -0.0355, and the 14-day reading is at -0.0505.
Analyst Ratings
In its analyst report released on March 24, 2023, Bryan Garnier began covering Adaptimmune Therapeutics plc (NASDAQ: ADAP). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Adaptimmune Therapeutics plc (ADAP) an Overweight rating. ADAP is a stock that is recommended for selling by 1 brokerage firm, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.
What is ADAP’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.00 and $10.00, with a median target price of $3.50. In analyzing these forecasts, the average price target given by analysts for Adaptimmune Therapeutics plc (ADAP) is $4.83.
